The U.S. Food and Drug Administration recently approved a treatment that combines an immunotherapy drug and chemotherapy for triple negative breast cancer, but not all cases of this aggressive form of breast cancer responded in clinical studies. UNC Lineberger researchers discovered biological clues that could help identify which tumors might respond to the combination treatment.
Their findings, published in the journal Cell, were drawn from studies in mice and an analysis of data from six clinical trials. If confirmed in future studies, the insights could help guide patients to the right treatments, sparing them from those that are not effective. It also could lead to an approach to make the drugs work in cancers that don’t initially respond.
To learn more, see original article at: https://www.sciencedaily.com/releases/2019/11/191114115940.htm
